We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sulforaphane Blocks Prostate Cancer by Stabilizing a DNA Methylation Pathway

By LabMedica International staff writers
Posted on 14 Mar 2012
Cancer researchers have identified another molecular pathway linked to inhibition of the growth of prostate cancer cells by sulforaphane.

Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, has been shown to block growth of prostate cancer cells without causing damage to normal prostate tissue. More...
SFN is an organosulfur compound that has been found to exhibit anticancer, antidiabetic, and antimicrobial properties in various experimental models. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts, or cabbages. The enzyme myrosinase transforms glucoraphanin, a glucosinolate, into sulforaphane upon damage to the plant (such as from chewing). Young sprouts of broccoli and cauliflower are particularly rich in glucoraphanin.

Investigators at Oregon State University (Corvallis, USA) had shown in previous studies that the modulation of epigenetic marks, such as inhibition of histone deacetylase (HDAC) enzymes, contributed to the antiproliferative effects of SFN. However, the effects of SFN on other common epigenetic marks such as DNA methylation have not been studied thoroughly.

As promoter hyper-methylation of cyclin D2, a major regulator of the cell cycle, has been shown to correlate with prostate cancer progression, and restoration of cyclin D2 expression exerts antiproliferative effects on prostate cancer cells; the current study was designed to investigate the effects of SFN on the DNA methylation status of cyclin D2 promoter, and how alteration in promoter methylation impacts cyclin D2 gene expression in prostate cancer cells.

Results published in the October 26, 2011, issue of the journal Clinical Epigenetics demonstrated the ability of SFN to modulate epigenetically cyclin D2 expression. SFN significantly decreased the expression of DNA methyltransferases (DNMTs), especially DNMT1 and DNMT3b. Furthermore, SFN significantly decreased methylation in cyclin D2 promoter regions containing c-Myc and multiple Sp1 binding sites. Reduced methlyation of cyclin D2 promoter corresponded to an increase in cyclin D2 transcript levels, suggesting that SFN may de-repress methylation-silenced cyclin D2 by impacting epigenetic pathways.

“It appears that DNA methylation and HDAC inhibition, both of which can be influenced by sulforaphane, work in concert with each other to maintain proper cell function,” said senior author Dr. Emily Ho, associate professor of nutrition and exercise sciences at Oregon State University. “They sort of work as partners and talk to each other. With these processes, the key is balance. DNA methylation is a natural process, and when properly controlled is helpful. But when the balance gets mixed up it can cause havoc, and that is where some of these critical nutrients are involved. They help restore the balance.”

“Cancer is very complex and it is usually not just one thing that has gone wrong,” said Dr. Ho. “It is increasingly clear that sulforaphane is a real multitasker. The more we find out about it, the more benefits it appears to have.”

Related Links:

Oregon State University




New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Genai-based pathological assessment workflow for lung adenocarcinoma (Shen J. et al., Int J Surg 111(7): 4252–4262; 2025)

Generative AI Demonstrates Expert-Level Pathological Assessment of Lung Cancer

Lung adenocarcinoma is one of the most difficult cancers to diagnose accurately, requiring pathologists to spend extensive time examining tissue samples under microscopes to determine tumor grades and... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.